|
Market Closed -
Bombay S.E.
06:02:25 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 2,946.60 INR | -1.61% |
|
-2.67% | +19.25% |
| 08-03 | GSK India first-quarter profit rises on steady vaccine demand | RE |
| 08-03 | GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: GlaxoSmithKline Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 281,714 | 224,319 | 329,173 | 487,432 | 386,822 | 499,172 | - |
| Change | - | -20.37% | 46.74% | 48.08% | -20.64% | 29.04% | - |
| Enterprise Value (EV) | 256,351 | 207,663 | 329,173 | 487,432 | 386,822 | 499,172 | 499,172 |
| Change | - | -18.99% | 58.51% | 48.08% | -20.64% | 29.04% | 0% |
| P/E | 16.6x | 36.7x | 55.8x | 52.5x | 37.3x | 42.8x | 37.2x |
| PBR | 10.6x | 12.9x | 18.5x | 25x | 17.1x | 18.8x | 15.8x |
| PEG | - | -0.6x | -16.49x | 0.9x | 3.2x | 3.4x | 2.5x |
| Capitalization / Revenue | 8.59x | 6.9x | 9.53x | 13x | 10.1x | 11.7x | 10.6x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 11.7x | 10.6x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 33.6x | 29.2x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 34x | 29.2x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 41.6x | 37.9x |
| FCF Yield | 2.75% | 1.96% | 1.67% | 2.6% | 2.19% | 2.4% | 2.64% |
| Dividend per Share 2 | 30 | 32 | 32 | 42 | 57 | 29.5 | 29.5 |
| Rate of return | 1.8% | 2.42% | 1.65% | 1.46% | 2.5% | 1% | 1% |
| EPS 2 | 100 | 36.05 | 34.83 | 54.76 | 61.15 | 68.78 | 79.18 |
| Distribution rate | 30% | 88.8% | 91.9% | 76.7% | 93.2% | 42.9% | 37.3% |
| Net sales 1 | 32,780 | 32,517 | 34,537 | 37,492 | 38,217 | 42,568 | 47,241 |
| EBITDA 1 | 8,273 | 8,043 | 9,087 | 11,774 | 13,092 | 14,836 | 17,070 |
| EBIT 1 | 7,592 | 7,385 | 8,390 | 11,106 | 12,428 | 14,698 | 17,112 |
| Net income 1 | 16,947 | 6,107 | 5,900 | 9,276 | 10,360 | 11,654 | 13,418 |
| Net Debt | -25,363 | -16,656 | - | - | - | - | - |
| Reference price 2 | 1,662.95 | 1,324.15 | 1,943.10 | 2,877.30 | 2,283.40 | 2,946.60 | 2,946.60 |
| Nbr of stocks (in thousands) | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | 169,406 | - |
| Announcement Date | 5/16/22 | 5/17/23 | 5/17/24 | 5/13/25 | 5/13/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 43.7x | - | - | 0.99% | 5.35B | |
| 33.02x | 11.99x | 24.3x | 0.6% | 1,034B | |
| 29.7x | - | - | 1.98% | 654B | |
| 33.18x | 7.69x | 15.99x | 2.64% | 459B | |
| 19.36x | 4.61x | 11.42x | 2.88% | 343B | |
| 22.91x | 5.89x | 14.6x | 2.71% | 307B | |
| 20.82x | 4.27x | 12.21x | 2.06% | 251B | |
| 27.71x | 7.15x | 12.7x | 2.3% | 237B | |
| 13.18x | 4.74x | 9.88x | 3.82% | 202B | |
| -45.81x | 6.6x | 25.78x | 2.2% | 186B | |
| Average | 19.78x | 6.62x | 15.86x | 2.22% | 367.69B | |
| Weighted average by Cap. | 24.10x | 8.04x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 500660 Stock
- Valuation GlaxoSmithKline Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
